Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Surgical Endoscopy
Published in: Surgical Endoscopy 6/2011

Open Access 01-06-2011

Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal reflux disease

Authors: Reginald C. W. Bell, Katherine D. Freeman

Published in: Surgical Endoscopy | Issue 6/2011

Login to get access

Abstract

Background

Transoral treatment of gastroesophageal reflux disease (GERD) using the EsophyX device enables creation of an esophagogastric fundoplication with potential for better control of reflux than gastrogastric techniques. Efficacy and safety of a rotational/longitudinal esophagogastric transoral incisionless fundoplication (TIF) was evaluated retrospectively using subjective and objective outcomes.

Methods

Thirty-seven consecutive patients on antisecretory medication and with proven gastroesophageal reflux and limited hiatal hernia underwent TIF for persistent GERD symptoms. Five patients were reoperations for failed laparoscopic fundoplication.

Results

Of the 37 treated patients, 57% were female. The median age was 58 (range = 20–81) years and BMI was 25.5 (range = 15.9–36.1) kg/m2. Sixty-eight percent indicated GERD-associated cough, asthma, or aspiration as a primary complaint and 32% complained of heartburn or regurgitation. The TIF procedures created tight wraps of 230°–330° extending 3–4 cm above the Z-line. Two complications occurred: one mediastinal abscess treated laparoscopically and one postoperative bleeding requiring transfusion. At 6 (range = 3–14) months median follow-up TIF resulted in a significant improvement of both atypical and typical symptoms in 64% and 70–80% of patients, respectively, as indicated by the corresponding GERD health-related quality of life (HRQL) and reflux symptom index (RSI) score reduction by 50% or more compared to baseline on proton pump inhibitors (PPIs). No patient reported problems with dysphagia, bloating, or excess flatulence, and 82% were not taking any PPIs. Reflux characteristics were significantly improved and normalized in 61, 89, and 56% of patients in terms of acid exposure, number of refluxates, and DeMeester scores, respectively. TIF was effective in treating GERD in 75% of patients among whom 54% were in a complete “remission” and 21% were “improved.” The remaining 25% were considered failures, and five (13.5%) patients underwent revision.

Conclusion

Rotational/longitudinal esophagogastric fundoplication using the EsophyX device significantly improved symptomatic and objective outcomes in over 70% of patients at median 6-month follow-up. Post-fundoplication side effects were not reported after TIF.
Literature
1.
Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III (1997) Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112:1448–1456PubMedCrossRef
2.
Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, Brill JV (2008) American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 135:1383–1391, 1391.e1–e5
3.
Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G, van Oudvorst A, Dalvag A, Junghard O, Wiklund I (1998) Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 10:119–124PubMedCrossRef
4.
Castell DO, Murray JA, Tutuian R, Orlando RC, Arnold R (2004) Review article: the pathophysiology of gastro-oesophageal reflux disease - oesophageal manifestations. Aliment Pharmacol Ther 20(Suppl 9):14–25PubMedCrossRef
5.
Fass R (2007) Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 67:1521–1530PubMedCrossRef
6.
Hunt RH, Yuan Y, Yaghoobi M (2007) GERD: new strategies and new failures. J Clin Gastroenterol 41(Suppl 2):S72–S80CrossRef
7.
Swoger J, Ponsky J, Hicks DM, Richter JE, Abelson TI, Milstein C, Qadeer MA, Vaezi MF (2006) Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. Clin Gastroenterol Hepatol 4:433–441PubMedCrossRef
8.
Vaezi MF, Richter JE, Stasney CR, Spiegel JR, Iannuzzi RA, Crawley JA, Hwang C, Sostek MB, Shaker R (2006) Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 116:254–260PubMedCrossRef
9.
Hill LD, Kozarek RA, Kraemer SJ, Aye RW, Mercer CD, Low DE, Pope CE 2nd (1996) The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc 44:541–547PubMedCrossRef
10.
Perry KA, Enestvedt CK, Lorenzo CS, Schipper P, Schindler J, Morris CD, Nason K, Luketich JD, Hunter JG, Jobe BA (2008) The integrity of esophagogastric junction anatomy in patients with isolated laryngopharyngeal reflux symptoms. J Gastrointest Surg 12:1880–1887PubMedCrossRef
11.
Seltman AK, Kahrilas PJ, Chang EY, Mori M, Hunter JG, Jobe BA (2006) Endoscopic measurement of cardia circumference as an indicator of GERD. Gastrointest Endosc 63:22–31PubMedCrossRef
12.
Hunter JG, Trus TL, Branum GD, Waring JP, Wood WC (1996) A physiologic approach to laparoscopic fundoplication for gastroesophageal reflux disease. Ann Surg 223:673–685PubMedCrossRef
13.
Sala E, Salminen P, Simberg S, Koskenvuo J, Ovaska J (2008) Laryngopharyngeal reflux disease treated with laparoscopic fundoplication. Dig Dis Sci 53:2397–2404PubMedCrossRef
14.
Walker SJ, Holt S, Sanderson CJ, Stoddard CJ (1992) Comparison of Nissen total and Lind partial transabdominal fundoplication in the treatment of gastro-oesophgeal reflux. Br J Surg 79:410–414PubMedCrossRef
15.
Westcott CJ, Hopkins MB, Bach K, Postma GN, Belafsky PC, Koufman JA (2004) Fundoplication for laryngopharyngeal reflux disease. J Am Coll Surg 199:23–30PubMedCrossRef
16.
Lundell L (2004) Complications after anti-reflux surgery. Best Pract Res Clin Gastroenterol 18:935–945PubMed
17.
Cadiere GB, Buset M, Muls V, Rajan A, Rosch T, Eckardt AJ, Weerts J, Bastens B, Costamagna G, Marchese M, Louis H, Mana F, Sermon F, Gawlicka AK, Daniel MA, Deviere J (2008) Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg 32:1676–1688PubMedCrossRef
18.
Cadiere GB, Van Sante N, Graves JE, Gawlicka AK, Rajan A (2009) Two-year results of a feasibility study on antireflux transoral incisionless fundoplication (TIF) using EsophyX. Surg Endosc 23:957–964PubMedCrossRef
19.
Repici A, Fumagalli U, Malesci A, Barbera R, Gambaro C, Rosati R (2010) Endoluminal fundoplication (ELF) for GERD using EsophyX: a 12-month follow-up in a single-center experience. J Gastrointest Surg 14:1–6PubMedCrossRef
20.
Testoni PA, Corsetti M, Di Pietro S, Castellaneta AG, Vailati C, Masci E, Passaretti S (2010) Effect of transoral incisionless fundoplication on symptoms, PPI use, and pH-impedance refluxes of GERD patients. World J Surg 34:750–757PubMedCrossRef
21.
22.
Bell RC, Hanna P, Mills MR, Bowrey D (1999) Patterns of success and failure with laparoscopic Toupet fundoplication. Surg Endosc 13:1189–1194PubMedCrossRef
23.
Belafsky PC, Postma GN, Koufman JA (2002) Validity and reliability of the reflux symptom index (RSI). J Voice 16(2):274–279
24.
Velanovich V (2007) The development of the GERD-HRQL symptom severity instrument. Dis Esophagus 20:130–134PubMedCrossRef
25.
Bell RC, Cadiere GB (2010) Transoral esophago-gastric fundoplication: technical and safety considerations. Surg Endosc (accepted)
26.
Demyttenaere SV, Bergman S, Pham T, Anderson J, Dettorre R, Melvin WS, Mikami DJ (2010) Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population. Surg Endosc 24:854–858PubMedCrossRef
27.
Jobe BA, O’Rourke RW, McMahon BP, Gravesen F, Lorenzo C, Hunter JG, Bronner M, Kraemer SJ (2008) Transoral endoscopic fundoplication in the treatment of gastroesophageal reflux disease: the anatomic and physiologic basis for reconstruction of the esophagogastric junction using a novel device. Ann Surg 248:69–76PubMedCrossRef
28.
Velanovich V, Vallance SR, Gusz JR, Tapia FV, Harkabus MA (1996) Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg 183:217–224PubMed
29.
Tseng D, Rizvi AZ, Fennerty MB, Jobe BA, Diggs BS, Sheppard BC, Gross SC, Swanstrom LL, White NB, Aye RW, Hunter JG (2005) Forty-eight-hour pH monitoring increases sensitivity in detecting abnormal esophageal acid exposure. J Gastrointest Surg 9:1043–1051PubMedCrossRef
30.
Tutuian R, Castell DO (2006) Diagnostic procedures in GERD: principles and values of esophageal manometry and pH-monitoring. In: Granderath FA, Kamolz T, Pointner R (eds) Gastroesophageal reflux disease: principles of disease, diagnosis, and treatment. Springer-Verlag, New York, pp 121–138
31.
Pandolfino JE, Kwiatek MA (2008) Use and utility of the Bravo pH capsule. J Clin Gastroenterol 42:571–578PubMedCrossRef
32.
Zerbib F, des Varannes SB, Roman S, Pouderoux P, Artigue F, Chaput U, Mion F, Caillol F, Verin E, Bommelaer G, Ducrotte P, Galmiche JP, Sifrim D (2005) Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther 22:1011–1021PubMedCrossRef
33.
Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L (1999) Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 45:172–180PubMedCrossRef
34.
DeVault KR, Castell DO (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100:190–200PubMedCrossRef
35.
Bredenoord AJ, Dent J (2007) Proton pump inhibitor-therapy refractory gastro-oesophageal reflux disease patients, who are they? Gut 56:593–594PubMedCrossRef
36.
Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO (2006) Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 93:1483–1487PubMedCrossRef
37.
Bredenoord AJ, Draaisma WA, Weusten BL, Gooszen HG, Smout AJ (2008) Mechanisms of acid, weakly acidic and gas reflux after anti-reflux surgery. Gut 57:161–166PubMedCrossRef
38.
Spechler SJ (2009) Surgery for gastroesophageal reflux disease: esophageal impedance to progress? Clin Gastroenterol Hepatol 7:1264–1265PubMedCrossRef
39.
Jafri SM, Arora G, Triadafilopoulos G (2009) What is left of the endoscopic antireflux devices? Curr Opin Gastroenterol 25:352–357PubMedCrossRef
40.
Rothstein RI (2008) Endoscopic therapy of gastroesophageal reflux disease: outcomes of the randomized-controlled trials done to date. J Clin Gastroenterol 42:594–602PubMedCrossRef
41.
42.
Pearl JP, Ponsky JL (2008) Natural orifice translumenal endoscopic surgery: a critical review. J Gastrointest Surg 12:1293–1300PubMedCrossRef
43.
44.
Milkes D, Gerson LB, Triadafilopoulos G (2004) Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 99:991–996PubMedCrossRef
45.
Portale G, Peters J, Hsieh CC, Tamhankar A, Arain M, Hagen J, Demeester S, Demeester T (2007) When are reflux episodes symptomatic? Dis Esophagus 20:47–52PubMedCrossRef
46.
Grigolon A, Cantu P, Savojardo D, Conte D, Penagini R (2008) Esophageal acid exposure on proton pump inhibitors in unselected asymptomatic gastroesophageal reflux disease patients. J Clin Gastroenterol 42:969–973PubMedCrossRef
47.
Sweis R, Fox M, Anggiansah R, Anggiansah A, Basavaraju K, Canavan R, Wong T (2009) Patient acceptance and clinical impact of Bravo monitoring in patients with previous failed catheter-based studies. Aliment Pharmacol Ther 29:669–676PubMedCrossRef
48.
von Renteln D, Schmidt D, Riecken B, Caca K (2010) Evaluating outcomes of endoscopic full-thickness plication for gastroesophageal reflux disease (GERD) with impedance monitoring. Surg Endosc 24:1040–1048CrossRef
49.
50.
Metadata
Title
Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal reflux disease
Authors
Reginald C. W. Bell
Katherine D. Freeman
Publication date
01-06-2011
Publisher
Springer-Verlag
Published in
Surgical Endoscopy / Issue 6/2011
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-010-1497-9

Other articles of this Issue 6/2011

Surgical Endoscopy 6/2011 Go to the issue

Editorial

Endoscopic surgery through single-port incision: time for a trial?

OriginalPaper

Plasma levels of angiostatin and endostatin remain unchanged for the first 3 weeks after colorectal cancer surgery

OriginalPaper

Outcome of 141 cases of self-expandable metallic stent placements for malignant and benign colorectal strictures in a single center

OriginalPaper

Gut oxygenation and oxidative damage during and after laparoscopic and open left-sided colon resection: a prospective, randomized, controlled clinical trial

OriginalPaper

A feasibility study on the expanded indication for endoscopic submucosal dissection of early gastric cancer

Technique

Uniportal video-assisted thoracic surgery for primary spontaneous pneumothorax using a single-incision laparoscopic surgery port: a feasible and safe procedure